Project Grant HT94252310858
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
The University of California, Los Angeles (UCLA) was awarded a $961,089 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420).
The grant will fund research targeting mitochondrial defects in kidney cancer from September 1, 2022 to August 31, 2025. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military...
This $472,500 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the University of California, Los Angeles (UCLA) in developing a next-generation, off-the-shelf CAR-NKT cell therapy for metastatic clear cell renal cell carcinoma. The two-year award, running from September 2024 to September 2026, enables UCLA's research efforts to advance this innovative cancer treatment approach. As a prime grantee, UCLA will...
This $708,750 Project Grant awarded by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) supports the development of a next-generation, off-the-shelf CAR-NKT cell therapy for treating metastatic clear cell renal cell carcinoma. The award, which runs from September 2024 through September 2026, was granted to the University of California, Los Angeles (UCLA) acting through its Office of Research Administration. As the prime awardee, UCLA will leverage its...
The University of California, Los Angeles (UCLA) was awarded a $1.56 million Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) for the period of June 30, 2022 to June 29, 2025.
The grant will support research to exploit DNA repair defects in renal cell carcinoma that is deficient in Krebs cycle enzymes. Specifically, the university will identify efficacious combinations of DNA damage response inhibitors in...
This federal Project Grant award of $1,163,420.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of California, Davis (UC Davis) for the period of September 30, 2024 through September 29, 2028. The award will support research to investigate the "functional and phenotypic metabolic transitions governing disease state in clear cell renal cell carcinoma." As a prominent public research university, UC...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $557,438 project grant to the University of California, Los Angeles (UCLA) to investigate UCHL1 as a novel minimally invasive molecular indicator and therapeutic target for small cell lung cancer. This 2-year research project runs from September 15, 2023 to September 14, 2025 and will be conducted through UCLA's Office of Research Administration division. As a prime grantee, UCLA has also...
The U.S. Department of Defense's Defense Health Agency awarded a $395,202 Project Grant to The University of Texas Southwestern Medical Center in Dallas, Texas under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "PET IMAGING OF HIF 2A IN RENAL CANCER," supports research to develop new imaging techniques for detecting and monitoring kidney cancer in military personnel and veterans. The three-year award, running from September 1, 2023 to August...
This $769,073 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research at the Royal Institution for the Advancement of Learning / McGill Office of Sponsored Research Division to define and target cancer cell-intrinsic vulnerabilities in renal cell carcinoma. The 3-year award, starting on August 1, 2024, will enable the university to conduct innovative scientific studies aimed at improving health outcomes for military...
The Defense Health Agency has awarded a $893,000 Project Grant to the University of California, Los Angeles (UCLA) - Office of Research Administration to conduct research under the Military Medical Research and Development program (CFDA 12.420). This four-year grant, effective August 15, 2023 through August 14, 2027, will support UCLA's efforts to investigate the EGFR signaling network in glioblastoma, an aggressive form of brain cancer. As the prime grantee, UCLA will leverage its research...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the...